CA2709903A1 - Compositions opioides orales comportant un antagoniste opioide - Google Patents

Info

Publication number

CA2709903A1

CA2709903A1 CA2709903A CA2709903A CA2709903A1 CA 2709903 A1 CA2709903 A1 CA 2709903A1 CA 2709903 A CA2709903 A CA 2709903A CA 2709903 A CA2709903 A CA 2709903A CA 2709903 A1 CA2709903 A1 CA 2709903A1

Authority

CA

Canada

Prior art keywords

antagonist

release

missing

opioid

rule

Prior art date

2007-12-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 239000000203 mixture Substances 0.000 title claims abstract description 109
• 239000003401 opiate antagonist Substances 0.000 title description 26
• 239000005557 antagonist Substances 0.000 claims abstract description 137
• 238000000034 method Methods 0.000 claims abstract description 66
• 239000000556 agonist Substances 0.000 claims abstract description 21
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
• 229960003086 naltrexone Drugs 0.000 claims description 69
• DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 68
• 230000000202 analgesic effect Effects 0.000 claims description 18
• JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 claims description 6
• 230000036470 plasma concentration Effects 0.000 claims description 5
• 230000014759 maintenance of location Effects 0.000 abstract description 109
• 208000002193 Pain Diseases 0.000 abstract description 80
• 230000036407 pain Effects 0.000 abstract description 76
• 229920000642 polymer Polymers 0.000 abstract description 44
• 238000004519 manufacturing process Methods 0.000 abstract description 4
• 239000003814 drug Substances 0.000 description 119
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 92
• 239000000463 material Substances 0.000 description 90
• -1 Ievaallorphaai Chemical compound 0.000 description 65
• 239000003795 chemical substances by application Substances 0.000 description 64
• 229940124597 therapeutic agent Drugs 0.000 description 62
• 229940079593 drug Drugs 0.000 description 55
• 239000008188 pellet Substances 0.000 description 55
• 239000002552 dosage form Substances 0.000 description 50
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
• 229960005181 morphine Drugs 0.000 description 47
• 239000000454 talc Substances 0.000 description 39
• 229910052623 talc Inorganic materials 0.000 description 39
• 229920002678 cellulose Polymers 0.000 description 35
• 235000010980 cellulose Nutrition 0.000 description 35
• GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 35
• 238000011282 treatment Methods 0.000 description 34
• 239000001913 cellulose Substances 0.000 description 33
• 230000000694 effects Effects 0.000 description 33
• 238000009472 formulation Methods 0.000 description 33
• 239000002253 acid Substances 0.000 description 31
• 239000006185 dispersion Substances 0.000 description 30
• 150000003839 salts Chemical class 0.000 description 30
• 239000012730 sustained-release form Substances 0.000 description 30
• 229920001577 copolymer Polymers 0.000 description 29
• 239000000243 solution Substances 0.000 description 27
• 238000013268 sustained release Methods 0.000 description 27
• 239000003826 tablet Substances 0.000 description 26
• 230000001225 therapeutic effect Effects 0.000 description 25
• 229940089053 kadian Drugs 0.000 description 23
• 230000002209 hydrophobic effect Effects 0.000 description 22
• 239000010410 layer Substances 0.000 description 21
• 239000013543 active substance Substances 0.000 description 20
• 238000000576 coating method Methods 0.000 description 20
• 239000006186 oral dosage form Substances 0.000 description 20
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• 239000002775 capsule Substances 0.000 description 19
• 239000003402 opiate agonist Substances 0.000 description 19
• FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 18
• 210000001035 gastrointestinal tract Anatomy 0.000 description 18
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 18
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
• 239000011248 coating agent Substances 0.000 description 17
• 235000000346 sugar Nutrition 0.000 description 17
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 16
• 239000000654 additive Substances 0.000 description 16
• 230000002411 adverse Effects 0.000 description 16
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 15
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 15
• 229960002085 oxycodone Drugs 0.000 description 15
• 239000011734 sodium Substances 0.000 description 15
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 15
• 230000008859 change Effects 0.000 description 14
• 230000001684 chronic effect Effects 0.000 description 14
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 14
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 13
• 239000002981 blocking agent Substances 0.000 description 13
• 239000004014 plasticizer Substances 0.000 description 13
• NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 12
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 12
• 238000013270 controlled release Methods 0.000 description 12
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 12
• 229960000240 hydrocodone Drugs 0.000 description 12
• 229940005483 opioid analgesics Drugs 0.000 description 12
• 229910052708 sodium Inorganic materials 0.000 description 12
• 229940083542 sodium Drugs 0.000 description 12
• 239000007921 spray Substances 0.000 description 12
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 11
• 230000003204 osmotic effect Effects 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 239000000758 substrate Substances 0.000 description 11
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 11
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 10
• 230000000996 additive effect Effects 0.000 description 10
• 239000011324 bead Substances 0.000 description 10
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
• 229960004715 morphine sulfate Drugs 0.000 description 10
• 239000011780 sodium chloride Substances 0.000 description 10
• 239000001993 wax Substances 0.000 description 10
• 150000002148 esters Chemical class 0.000 description 9
• 239000003349 gelling agent Substances 0.000 description 9
• 150000002500 ions Chemical class 0.000 description 9
• 239000011159 matrix material Substances 0.000 description 9
• UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 9
• 229960004127 naloxone Drugs 0.000 description 9
• 239000000546 pharmaceutical excipient Substances 0.000 description 9
• 201000009032 substance abuse Diseases 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
• 229960001138 acetylsalicylic acid Drugs 0.000 description 8
• 235000014113 dietary fatty acids Nutrition 0.000 description 8
• 239000000975 dye Substances 0.000 description 8
• 229930195729 fatty acid Natural products 0.000 description 8
• 239000000194 fatty acid Substances 0.000 description 8
• 239000004615 ingredient Substances 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 238000002483 medication Methods 0.000 description 8
• 229940127240 opiate Drugs 0.000 description 8
• 229960005489 paracetamol Drugs 0.000 description 8
• 229920000058 polyacrylate Polymers 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 239000001856 Ethyl cellulose Substances 0.000 description 7
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
• 239000004359 castor oil Substances 0.000 description 7
• 235000019438 castor oil Nutrition 0.000 description 7
• 229960004126 codeine Drugs 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
• 229920001249 ethyl cellulose Polymers 0.000 description 7
• 235000019325 ethyl cellulose Nutrition 0.000 description 7
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 239000002085 irritant Substances 0.000 description 7
• 231100000021 irritant Toxicity 0.000 description 7
• 238000009533 lab test Methods 0.000 description 7
• 229920001277 pectin Polymers 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
• 206010041349 Somnolence Diseases 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 229920002301 cellulose acetate Polymers 0.000 description 6
• 201000010099 disease Diseases 0.000 description 6
• 230000002496 gastric effect Effects 0.000 description 6
• 229960002764 hydrocodone bitartrate Drugs 0.000 description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
• 230000003533 narcotic effect Effects 0.000 description 6
• 239000003921 oil Substances 0.000 description 6
• 235000019198 oils Nutrition 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 5
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 5
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
• 241000206607 Porphyra umbilicalis Species 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 150000001298 alcohols Chemical class 0.000 description 5
• 125000000217 alkyl group Chemical group 0.000 description 5
• 235000010323 ascorbic acid Nutrition 0.000 description 5
• 239000011668 ascorbic acid Substances 0.000 description 5
• 229960005070 ascorbic acid Drugs 0.000 description 5
• 230000004888 barrier function Effects 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 229960002069 diamorphine Drugs 0.000 description 5
• 150000002191 fatty alcohols Chemical class 0.000 description 5
• 239000012530 fluid Substances 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 229940014259 gelatin Drugs 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 229930195733 hydrocarbon Natural products 0.000 description 5
• 150000002430 hydrocarbons Chemical class 0.000 description 5
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 5
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 239000002198 insoluble material Substances 0.000 description 5
• 239000008101 lactose Substances 0.000 description 5
• 230000008018 melting Effects 0.000 description 5
• 238000002844 melting Methods 0.000 description 5
• 229910052751 metal Inorganic materials 0.000 description 5
• 239000002184 metal Substances 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 239000001814 pectin Substances 0.000 description 5
• 235000010987 pectin Nutrition 0.000 description 5
• 239000004417 polycarbonate Substances 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 239000008107 starch Substances 0.000 description 5
• 235000019698 starch Nutrition 0.000 description 5
• 239000005720 sucrose Substances 0.000 description 5
• 239000004094 surface-active agent Substances 0.000 description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
• 208000000094 Chronic Pain Diseases 0.000 description 4
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
• PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 4
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
• 229920003134 Eudragit® polymer Polymers 0.000 description 4
• 206010015535 Euphoric mood Diseases 0.000 description 4
• 240000007472 Leucaena leucocephala Species 0.000 description 4
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
• 206010028813 Nausea Diseases 0.000 description 4
• 239000008896 Opium Substances 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 208000032140 Sleepiness Diseases 0.000 description 4
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
• 239000000730 antalgic agent Substances 0.000 description 4
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
• 229960002504 capsaicin Drugs 0.000 description 4
• 235000017663 capsaicin Nutrition 0.000 description 4
• 229920006217 cellulose acetate butyrate Polymers 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 238000004090 dissolution Methods 0.000 description 4
• 238000013265 extended release Methods 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 4
• 239000000796 flavoring agent Substances 0.000 description 4
• 239000008187 granular material Substances 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 229960001410 hydromorphone Drugs 0.000 description 4
• 229920001600 hydrophobic polymer Polymers 0.000 description 4
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 210000003127 knee Anatomy 0.000 description 4
• 239000004310 lactic acid Substances 0.000 description 4
• 235000014655 lactic acid Nutrition 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 229940063557 methacrylate Drugs 0.000 description 4
• 229940063559 methacrylic acid Drugs 0.000 description 4
• 230000008693 nausea Effects 0.000 description 4
• 229960001027 opium Drugs 0.000 description 4
• 201000008482 osteoarthritis Diseases 0.000 description 4
• 230000000704 physical effect Effects 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 239000002464 receptor antagonist Substances 0.000 description 4
• 229940044551 receptor antagonist Drugs 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 229940116351 sebacate Drugs 0.000 description 4
• CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 3
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 229920000178 Acrylic resin Polymers 0.000 description 3
• 239000004925 Acrylic resin Substances 0.000 description 3
• 208000007848 Alcoholism Diseases 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• 229920002284 Cellulose triacetate Polymers 0.000 description 3
• 206010010774 Constipation Diseases 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
• 101100456896 Drosophila melanogaster metl gene Proteins 0.000 description 3
• 241001539473 Euphoria Species 0.000 description 3
• 206010019233 Headaches Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000018526 Narcotic-Related disease Diseases 0.000 description 3
• 229940127450 Opioid Agonists Drugs 0.000 description 3
• 102000003840 Opioid Receptors Human genes 0.000 description 3
• 108090000137 Opioid Receptors Proteins 0.000 description 3
• 239000008118 PEG 6000 Substances 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 229920002125 Sokalan® Polymers 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 3
• 206010047700 Vomiting Diseases 0.000 description 3
• NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
• 150000008065 acid anhydrides Chemical class 0.000 description 3
• 229940114077 acrylic acid Drugs 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 235000015107 ale Nutrition 0.000 description 3
• 239000011717 all-trans-retinol Substances 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 229940035676 analgesics Drugs 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 235000013871 bee wax Nutrition 0.000 description 3
• 239000012166 beeswax Substances 0.000 description 3
• 230000036765 blood level Effects 0.000 description 3
• 159000000007 calcium salts Chemical class 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 230000001055 chewing effect Effects 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 229940099112 cornstarch Drugs 0.000 description 3
• 229940111134 coxibs Drugs 0.000 description 3
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000002565 electrocardiography Methods 0.000 description 3
• 150000002170 ethers Chemical class 0.000 description 3
• 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
• 235000019634 flavors Nutrition 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 229930195712 glutamate Natural products 0.000 description 3
• 125000005456 glyceride group Chemical group 0.000 description 3
• 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 3
• 231100000869 headache Toxicity 0.000 description 3
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
• 229960001680 ibuprofen Drugs 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 239000003887 narcotic antagonist Substances 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 229940100688 oral solution Drugs 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
• 238000009597 pregnancy test Methods 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 150000003222 pyridines Chemical class 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 229940095064 tartrate Drugs 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 229960004380 tramadol Drugs 0.000 description 3
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 2
• OJHZNMVJJKMFGX-BWCYBWMMSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OJHZNMVJJKMFGX-BWCYBWMMSA-N 0.000 description 2
• DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
• BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 2
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 229920008347 Cellulose acetate propionate Polymers 0.000 description 2
• DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 2
• 235000005979 Citrus limon Nutrition 0.000 description 2
• 244000131522 Citrus pyriformis Species 0.000 description 2
• 240000000560 Citrus x paradisi Species 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 229920003152 Eudragit® RS polymer Polymers 0.000 description 2
• 229920002907 Guar gum Polymers 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
• JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
• 206010025476 Malabsorption Diseases 0.000 description 2
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
• CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
• DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
• 101150050331 PGIC gene Proteins 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 229920001800 Shellac Polymers 0.000 description 2
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
• 206010070863 Toxicity to various agents Diseases 0.000 description 2
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• 239000013504 Triton X-100 Substances 0.000 description 2
• 229940048053 acrylate Drugs 0.000 description 2
• 201000007930 alcohol dependence Diseases 0.000 description 2
• 235000019169 all-trans-retinol Nutrition 0.000 description 2
• WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
• 230000036592 analgesia Effects 0.000 description 2
• 125000000129 anionic group Chemical group 0.000 description 2
• 229940124623 antihistamine drug Drugs 0.000 description 2
• 239000003434 antitussive agent Substances 0.000 description 2
• 229940124584 antitussives Drugs 0.000 description 2
• 210000001188 articular cartilage Anatomy 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 229960001736 buprenorphine Drugs 0.000 description 2
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
• 229960001948 caffeine Drugs 0.000 description 2
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
• 235000013539 calcium stearate Nutrition 0.000 description 2
• 239000008116 calcium stearate Substances 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 229920003086 cellulose ether Polymers 0.000 description 2
• 229920006218 cellulose propionate Polymers 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 235000020971 citrus fruits Nutrition 0.000 description 2
• GPZLDQAEBHTMPG-UHFFFAOYSA-N clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 description 2
• 229950001604 clonitazene Drugs 0.000 description 2
• 239000008199 coating composition Substances 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 230000001186 cumulative effect Effects 0.000 description 2
• 229950002213 cyclazocine Drugs 0.000 description 2
• 239000000850 decongestant Substances 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 2
• RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 description 2
• 229950011187 dimenoxadol Drugs 0.000 description 2
• QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 description 2
• 229950004655 dimepheptanol Drugs 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• LQGIXNQCOXNCRP-UHFFFAOYSA-N dioxaphetyl butyrate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)OCC)CCN1CCOCC1 LQGIXNQCOXNCRP-UHFFFAOYSA-N 0.000 description 2
• 229950008972 dioxaphetyl butyrate Drugs 0.000 description 2
• SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 description 2
• 229960002500 dipipanone Drugs 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 208000002173 dizziness Diseases 0.000 description 2
• 239000010459 dolomite Substances 0.000 description 2
• 229910000514 dolomite Inorganic materials 0.000 description 2
• 235000013399 edible fruits Nutrition 0.000 description 2
• 230000000773 effect on pain Effects 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 description 2
• 229950010920 eptazocine Drugs 0.000 description 2
• 150000002169 ethanolamines Chemical class 0.000 description 2
• WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 2
• 229960000569 ethoheptazine Drugs 0.000 description 2
• FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 2
• 230000002743 euphoric effect Effects 0.000 description 2
• 239000003925 fat Substances 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 239000000576 food coloring agent Substances 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 230000009477 glass transition Effects 0.000 description 2
• 230000005484 gravity Effects 0.000 description 2
• 239000000665 guar gum Substances 0.000 description 2
• 235000010417 guar gum Nutrition 0.000 description 2
• 229960002154 guar gum Drugs 0.000 description 2
• 229920000591 gum Polymers 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 230000036571 hydration Effects 0.000 description 2
• 238000006703 hydration reaction Methods 0.000 description 2
• AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 239000003456 ion exchange resin Substances 0.000 description 2
• 229920003303 ion-exchange polymer Polymers 0.000 description 2
• 230000000622 irritating effect Effects 0.000 description 2
• IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 2
• 229950009272 isomethadone Drugs 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
• 229960003406 levorphanol Drugs 0.000 description 2
• 229940089568 lortab Drugs 0.000 description 2
• 159000000003 magnesium salts Chemical class 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 102000006240 membrane receptors Human genes 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 125000005395 methacrylic acid group Chemical group 0.000 description 2
• 229960001797 methadone Drugs 0.000 description 2
• NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 description 2
• 229950006080 metopon Drugs 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 description 2
• 239000004084 narcotic analgesic agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 201000005040 opiate dependence Diseases 0.000 description 2
• 239000000014 opioid analgesic Substances 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 229960003617 oxycodone hydrochloride Drugs 0.000 description 2
• 229960005118 oxymorphone Drugs 0.000 description 2
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229960000482 pethidine Drugs 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 description 2
• 229960004315 phenoperidine Drugs 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002203 pretreatment Methods 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 108090000623 proteins and genes Proteins 0.000 description 2
• 208000020016 psychiatric disease Diseases 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 230000000630 rising effect Effects 0.000 description 2
• 239000000932 sedative agent Substances 0.000 description 2
• 230000035807 sensation Effects 0.000 description 2
• 235000019615 sensations Nutrition 0.000 description 2
• 230000009919 sequestration Effects 0.000 description 2
• 239000004208 shellac Substances 0.000 description 2
• 229940113147 shellac Drugs 0.000 description 2
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
• 235000013874 shellac Nutrition 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• OGPIIGMUPMPMNT-UHFFFAOYSA-M sodium meclofenamate (anhydrous) Chemical compound [Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl OGPIIGMUPMPMNT-UHFFFAOYSA-M 0.000 description 2
• 159000000000 sodium salts Chemical class 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 238000005507 spraying Methods 0.000 description 2
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 238000011477 surgical intervention Methods 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 230000009747 swallowing Effects 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 235000019640 taste Nutrition 0.000 description 2
• 229960001402 tilidine Drugs 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 238000010200 validation analysis Methods 0.000 description 2
• 230000004584 weight gain Effects 0.000 description 2
• 235000019786 weight gain Nutrition 0.000 description 2
• NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
• ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 1
• XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
• RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
• OPEYVVLXBYHKDO-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OPEYVVLXBYHKDO-DANDVKJOSA-N 0.000 description 1
• ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
• GBBVHDGKDQAEOT-UHFFFAOYSA-N 1,7-dioxaspiro[5.5]undecane Chemical compound O1CCCCC11OCCCC1 GBBVHDGKDQAEOT-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
• DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
• JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
• WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
• SSONCJTVDRSLNK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;hydrochloride Chemical compound Cl.CC(=C)C(O)=O SSONCJTVDRSLNK-UHFFFAOYSA-N 0.000 description 1
• XUDUTRMKKYUAKI-UHFFFAOYSA-N 3-[1-(1-phenylethyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2C(NC3=CC=CC=C32)=O)CCN1C(C)C1=CC=CC=C1 XUDUTRMKKYUAKI-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
• PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
• KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• 101150052147 ALLC gene Proteins 0.000 description 1
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Natural products CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 244000303258 Annona diversifolia Species 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 101100232929 Caenorhabditis elegans pat-4 gene Proteins 0.000 description 1
• 229910021532 Calcite Inorganic materials 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 229920001747 Cellulose diacetate Polymers 0.000 description 1
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
• 241000272165 Charadriidae Species 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 235000019499 Citrus oil Nutrition 0.000 description 1
• 101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 description 1
• 206010009866 Cold sweat Diseases 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 241000518994 Conta Species 0.000 description 1
• 244000180278 Copernicia prunifera Species 0.000 description 1
• 235000010919 Copernicia prunifera Nutrition 0.000 description 1
• 201000006306 Cor pulmonale Diseases 0.000 description 1
• 241001327708 Coriaria sarmentosa Species 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 244000303965 Cyamopsis psoralioides Species 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• 208000034423 Delivery Diseases 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 241001184731 Eira Species 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 239000004593 Epoxy Substances 0.000 description 1
• 241001522296 Erithacus rubecula Species 0.000 description 1
• 229920003148 Eudragit® E polymer Polymers 0.000 description 1
• 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 239000004214 Fast Green FCF Substances 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
• 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
• 101000807533 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 26 Proteins 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 206010020591 Hypercapnia Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 206010022035 Initial insomnia Diseases 0.000 description 1
• 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
• 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 241000272168 Laridae Species 0.000 description 1
• OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 241000220225 Malus Species 0.000 description 1
• 235000011430 Malus pumila Nutrition 0.000 description 1
• 235000015103 Malus silvestris Nutrition 0.000 description 1
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
• 235000006679 Mentha X verticillata Nutrition 0.000 description 1
• 235000002899 Mentha suaveolens Nutrition 0.000 description 1
• 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 235000009421 Myristica fragrans Nutrition 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• LYAVXWPXKIFHBU-UHFFFAOYSA-N N-{2-[(1,2-diphenylhydrazinyl)carbonyl]-2-hydroxyhexanoyl}-6-aminohexanoic acid Chemical compound C=1C=CC=CC=1N(C(=O)C(O)(C(=O)NCCCCCC(O)=O)CCCC)NC1=CC=CC=C1 LYAVXWPXKIFHBU-UHFFFAOYSA-N 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
• UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
• 208000032234 No therapeutic response Diseases 0.000 description 1
• ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 235000019944 Olestra Nutrition 0.000 description 1
• 229920002230 Pectic acid Polymers 0.000 description 1
• 235000014676 Phragmites communis Nutrition 0.000 description 1
• 240000008474 Pimenta dioica Species 0.000 description 1
• 235000006990 Pimenta dioica Nutrition 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 206010038678 Respiratory depression Diseases 0.000 description 1
• 206010038743 Restlessness Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 206010039203 Road traffic accident Diseases 0.000 description 1
• 206010041235 Snoring Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 235000021536 Sugar beet Nutrition 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 208000001871 Tachycardia Diseases 0.000 description 1
• 206010043268 Tension Diseases 0.000 description 1
• 241000011102 Thera Species 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 240000006909 Tilia x europaea Species 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 241000383675 Trama Species 0.000 description 1
• 102000003929 Transaminases Human genes 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 description 1
• 102100037180 Ubiquitin carboxyl-terminal hydrolase 26 Human genes 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 description 1
• GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
• YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• PAAZCQANMCYGAW-UHFFFAOYSA-N acetic acid;2,2,2-trifluoroacetic acid Chemical compound CC(O)=O.OC(=O)C(F)(F)F PAAZCQANMCYGAW-UHFFFAOYSA-N 0.000 description 1
• ZLGVJFWQQPUXQU-UHFFFAOYSA-N acetic acid;butanoic acid;octanoic acid Chemical compound CC(O)=O.CCCC(O)=O.CCCCCCCC(O)=O ZLGVJFWQQPUXQU-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 229920006243 acrylic copolymer Polymers 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 229920013820 alkyl cellulose Polymers 0.000 description 1
• KGYFOSCXVAXULR-UHFFFAOYSA-N allylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1CC=C KGYFOSCXVAXULR-UHFFFAOYSA-N 0.000 description 1
• 229950004361 allylprodine Drugs 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 229910052586 apatite Inorganic materials 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 235000019658 bitter taste Nutrition 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 125000005587 carbonate group Chemical group 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
• 229960003184 carprofen Drugs 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 229960002798 cetrimide Drugs 0.000 description 1
• JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 229910001919 chlorite Inorganic materials 0.000 description 1
• 229910052619 chlorite group Inorganic materials 0.000 description 1
• QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
• 101150087654 chrnd gene Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
• 239000010500 citrus oil Substances 0.000 description 1
• 239000000571 coke Substances 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 229940124301 concurrent medication Drugs 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 239000000039 congener Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 229940124558 contraceptive agent Drugs 0.000 description 1
• 239000003433 contraceptive agent Substances 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000003001 depressive effect Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• USSIQXCVUWKGNF-KRWDZBQOSA-N dextromethadone Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-KRWDZBQOSA-N 0.000 description 1
• INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 description 1
• 229960003701 dextromoramide Drugs 0.000 description 1
• 229960004193 dextropropoxyphene Drugs 0.000 description 1
• XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
• RXTHKWVSXOIHJS-UHFFFAOYSA-N diampromide Chemical compound C=1C=CC=CC=1N(C(=O)CC)CC(C)N(C)CCC1=CC=CC=C1 RXTHKWVSXOIHJS-UHFFFAOYSA-N 0.000 description 1
• 229950001059 diampromide Drugs 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 229960001193 diclofenac sodium Drugs 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 1
• 229940099212 dilaudid Drugs 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 238000009506 drug dissolution testing Methods 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 206010013781 dry mouth Diseases 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000002895 emetic Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000000686 essence Substances 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
• PXDBZSCGSQSKST-UHFFFAOYSA-N etonitazene Chemical compound C1=CC(OCC)=CC=C1CC1=NC2=CC([N+]([O-])=O)=CC=C2N1CCN(CC)CC PXDBZSCGSQSKST-UHFFFAOYSA-N 0.000 description 1
• 229950004538 etonitazene Drugs 0.000 description 1
• CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
• 229950004155 etorphine Drugs 0.000 description 1
• 239000010642 eucalyptus oil Substances 0.000 description 1
• 229940044949 eucalyptus oil Drugs 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000003172 expectorant agent Substances 0.000 description 1
• 230000003419 expectorant effect Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 235000019240 fast green FCF Nutrition 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 229960002679 fentiazac Drugs 0.000 description 1
• 239000013020 final formulation Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000010579 first pass effect Methods 0.000 description 1
• 229950005722 flosulide Drugs 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 239000000989 food dye Substances 0.000 description 1
• 230000009246 food effect Effects 0.000 description 1
• 235000021471 food effect Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000008369 fruit flavor Substances 0.000 description 1
• 239000013538 functional additive Substances 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 239000011346 highly viscous material Substances 0.000 description 1
• 239000007970 homogeneous dispersion Substances 0.000 description 1
• 125000001145 hydrido group Chemical group *[H] 0.000 description 1
• 125000001183 hydrocarbyl group Chemical group 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• WTJBNMUWRKPFRS-UHFFFAOYSA-N hydroxypethidine Chemical compound C=1C=CC(O)=CC=1C1(C(=O)OCC)CCN(C)CC1 WTJBNMUWRKPFRS-UHFFFAOYSA-N 0.000 description 1
• 229950008496 hydroxypethidine Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000000147 hypnotic effect Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 229960004187 indoprofen Drugs 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
• 229950002252 isoxicam Drugs 0.000 description 1
• 235000015110 jellies Nutrition 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 229960003029 ketobemidone Drugs 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 229960000263 levallorphan Drugs 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
• 229950010274 lofentanil Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000001115 mace Substances 0.000 description 1
• 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
• HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 229960003803 meclofenamic acid Drugs 0.000 description 1
• 229960003464 mefenamic acid Drugs 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 238000007909 melt granulation Methods 0.000 description 1
• 239000001683 mentha spicata herb oil Substances 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 1
• 229950009131 metazocine Drugs 0.000 description 1
• 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
• 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 229940071088 methyl cocoyl taurate Drugs 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 239000010445 mica Substances 0.000 description 1
• 229910052618 mica group Inorganic materials 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000003595 mist Substances 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• GODGZZGKTZQSAL-VXFFQEMOSA-N myrophine Chemical compound C([C@@H]1[C@@H]2C=C[C@@H]([C@@H]3OC4=C5[C@]23CCN1C)OC(=O)CCCCCCCCCCCCC)C5=CC=C4OCC1=CC=CC=C1 GODGZZGKTZQSAL-VXFFQEMOSA-N 0.000 description 1
• 229950007471 myrophine Drugs 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
• 229960000805 nalbuphine Drugs 0.000 description 1
• 229960005297 nalmefene Drugs 0.000 description 1
• 229960000938 nalorphine Drugs 0.000 description 1
• 229960000858 naltrexone hydrochloride Drugs 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229960004300 nicomorphine Drugs 0.000 description 1
• HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 229940121367 non-opioid analgesics Drugs 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229950006134 normorphine Drugs 0.000 description 1
• 238000001584 occupational therapy Methods 0.000 description 1
• 239000008601 oleoresin Substances 0.000 description 1
• 239000007935 oral tablet Substances 0.000 description 1
• 229940096978 oral tablet Drugs 0.000 description 1
• 235000015205 orange juice Nutrition 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000000399 orthopedic effect Effects 0.000 description 1
• 229940051877 other opioids in atc Drugs 0.000 description 1
• 230000027758 ovulation cycle Effects 0.000 description 1
• 229940124583 pain medication Drugs 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 239000003415 peat Substances 0.000 description 1
• VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
• 229960005301 pentazocine Drugs 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 239000012169 petroleum derived wax Substances 0.000 description 1
• 235000019381 petroleum wax Nutrition 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000008180 pharmaceutical surfactant Substances 0.000 description 1
• LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 description 1
• 229950004540 phenadoxone Drugs 0.000 description 1
• ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
• 229960000897 phenazocine Drugs 0.000 description 1
• CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 description 1
• 229950011496 phenomorphan Drugs 0.000 description 1
• 150000002990 phenothiazines Chemical class 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
• 229920001281 polyalkylene Polymers 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000002685 polymerization catalyst Substances 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• ZXWAUWBYASJEOE-UHFFFAOYSA-N proheptazine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCCN(C)CC1C ZXWAUWBYASJEOE-UHFFFAOYSA-N 0.000 description 1
• XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 description 1
• 229950004345 properidine Drugs 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 description 1
• 229950003779 propiram Drugs 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000009325 pulmonary function Effects 0.000 description 1
• 235000019633 pungent taste Nutrition 0.000 description 1
• 239000010453 quartz Substances 0.000 description 1
• 239000011044 quartzite Substances 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 229940127558 rescue medication Drugs 0.000 description 1
• 239000012508 resin bead Substances 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000036387 respiratory rate Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229940110294 revia Drugs 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 229940071089 sarcosinate Drugs 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 230000001624 sedative effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 238000010008 shearing Methods 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
• 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 208000022925 sleep disturbance Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• DBKCLWTWMFVXQN-UHFFFAOYSA-M sodium sulfuric acid chloride Chemical compound [Na+].[Cl-].OS(O)(=O)=O DBKCLWTWMFVXQN-UHFFFAOYSA-M 0.000 description 1
• HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
• JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
• ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
• 239000007962 solid dispersion Substances 0.000 description 1
• 235000019721 spearmint oil Nutrition 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 229930188255 stemmin Natural products 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 229940013883 sucrose octaacetate Drugs 0.000 description 1
• 150000003445 sucroses Chemical class 0.000 description 1
• 229950005175 sudoxicam Drugs 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 239000007916 tablet composition Substances 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 239000012085 test solution Substances 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 239000003204 tranquilizing agent Substances 0.000 description 1
• 230000002936 tranquilizing effect Effects 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000012384 transportation and delivery Methods 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
• 239000001069 triethyl citrate Substances 0.000 description 1
• VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 238000009810 tubal ligation Methods 0.000 description 1
• 229940053347 vicoprofen Drugs 0.000 description 1
• 229940087652 vioxx Drugs 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 230000002618 waking effect Effects 0.000 description 1
• 229920003176 water-insoluble polymer Polymers 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229950007802 zidometacin Drugs 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
• 229960003414 zomepirac Drugs 0.000 description 1
• ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1